Avanos reports Q4 adjusted EPS $0.29 vs $0.43 prior year; FY2025 sales $701.2M up 1.9%

AVANOS MEDICAL, INC.

2025-FY EPS reported -$1.57 revenue$701,200,000

Q4 net sales $180.9M (+0.7% YoY); SNS segment up 8.7% to $115.1M; PM&R up 1.3% to $61.6M.
Q4 GAAP net loss $1.3M ($0.03 loss per share); adjusted net income $13.4M ($0.29 adjusted EPS).
Full-year 2025 net loss $72.9M; adjusted EBITDA $86.8M vs $107.6M in 2024.
Recorded $77M non-cash goodwill impairment on PM&R segment in Q2 2025.
2026 guidance: net sales $700-720M; adjusted diluted EPS $0.90-1.10.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.